NMRA
Neumora Therapeutics, Inc. Common Stock NASDAQ$2.44
After hrs
$2.34
+1.20%
Mkt Cap $398.7M
52w Low $0.61
60.2% of range
52w High $3.65
50d MA $2.63
200d MA $2.18
P/E (TTM)
-1.7x
EV/EBITDA
-0.5x
P/B
3.8x
Debt/Equity
0.0x
ROE
-228.1%
P/FCF
-1.4x
RSI (14)
—
ATR (14)
—
Beta
3.12
50d MA
$2.63
200d MA
$2.18
Avg Volume
1.3M
About
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.34 | -0.35 | -2.9% | 2.87 | +0.7% | -1.4% | -8.0% | -10.5% | -12.5% | -13.9% | -28.2% | — |
| Nov 6, 2025 | AMC | -0.34 | -0.35 | -2.9% | 2.58 | -3.1% | -0.8% | +8.9% | +6.6% | +10.9% | +4.3% | -15.1% | — |
| Aug 6, 2025 | AMC | -0.38 | -0.33 | +13.2% | 1.59 | +4.4% | +3.8% | -8.2% | -9.4% | -5.7% | -1.9% | +5.7% | — |
| May 12, 2025 | AMC | -0.40 | -0.42 | -5.0% | 0.69 | -0.2% | -1.9% | -11.2% | -3.9% | +1.3% | -0.3% | +33.1% | — |
| Mar 3, 2025 | AMC | -0.46 | -0.37 | +19.6% | 1.41 | -2.8% | +0.0% | +1.4% | +7.8% | +5.7% | -5.0% | -33.3% | — |
| Nov 12, 2024 | AMC | -0.38 | -0.45 | -18.4% | 11.31 | +1.5% | -4.7% | +3.4% | -4.2% | -13.0% | -12.8% | -6.5% | — |
| Aug 6, 2024 | AMC | -0.37 | -0.37 | +0.0% | 11.99 | -0.3% | -1.7% | -6.3% | -6.1% | -6.9% | -5.8% | -10.0% | — |
| May 7, 2024 | AMC | -0.35 | -0.34 | +2.9% | 9.81 | -2.1% | -4.0% | -0.4% | -6.3% | -8.7% | -2.3% | +1.2% | — |
| Mar 7, 2024 | AMC | -0.65 | -0.71 | -9.2% | 19.00 | +3.3% | -5.3% | -5.0% | -8.7% | -22.1% | -20.4% | -22.6% | — |
| Nov 1, 2023 | AMC | -0.36 | -1.14 | -216.7% | 10.79 | -0.4% | +1.2% | +9.8% | +5.7% | +7.5% | -1.5% | +14.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Guggenheim | Maintains | Buy → Buy | — | $1.93 | $1.91 | -1.0% | +1.0% | +8.3% | +3.6% | +9.8% | +10.4% |
| Mar 31 | Needham | Maintains | Buy → Buy | — | $1.93 | $1.91 | -1.0% | +1.0% | +8.3% | +3.6% | +9.8% | +10.4% |
| Feb 17 | William Blair | Upgrade | Market Perform → Outperform | — | $3.20 | $3.35 | +4.7% | +10.6% | +12.2% | +8.8% | +5.9% | +7.8% |
| Dec 1 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $2.24 | $2.53 | +12.9% | +8.0% | -0.4% | +1.3% | +1.8% | -0.9% |
| Nov 17 | Stifel | Maintains | Hold → Hold | — | $2.65 | $2.62 | -1.1% | -2.3% | +0.4% | -4.2% | -10.9% | -12.1% |
| Oct 28 | Needham | Maintains | Buy → Buy | — | $2.69 | $2.70 | +0.4% | -3.7% | -7.1% | +8.9% | +12.3% | +11.9% |
| Oct 27 | Guggenheim | Upgrade | Neutral → Buy | — | $2.63 | $2.68 | +1.9% | +2.3% | -1.5% | -4.9% | +11.4% | +14.8% |
| Sep 16 | JP Morgan | Downgrade | Neutral → Underweight | — | $1.52 | $1.50 | -1.3% | -1.3% | -4.6% | +3.3% | +15.8% | +13.8% |
| Jul 16 | Mizuho | Maintains | Outperform → Outperform | — | $1.45 | $1.53 | +5.5% | -3.4% | +17.9% | +27.6% | +35.2% | +30.3% |
| May 13 | Needham | Maintains | Buy → Buy | — | $0.69 | $0.69 | -0.2% | -1.9% | -11.2% | -3.9% | +1.3% | -0.3% |
Recent Filings
8-K
Unknown — 8-K Filing
Neumora's clinical-stage pipeline and cash position updates will clarify runway for drug development and whether the company can reach key milestones before requiring additional financing, directly impacting dilution risk.
Mar 30
8-K · 7.01
! Medium
Neumora Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Neumora Therapeutics (NMRA) disclosed a presentation through Regulation FD, providing investors with updated information about the company's business and strategy.
Feb 11
Data updated apr 26, 2026 3:20pm
· Source: massive.com